Piramal Pharma Solutions Commissions Microbiology Lab at $85 Million Lexington Expansion Site in Kentucky, US

Piramal Pharma Solutions has brought a new microbiology laboratory into routine GMP operation at its sterile injectable manufacturing site in Lexington, Kentucky. The laboratory was released for routine GMP use on September 11, 2026, and shortly afterwards the facility's new sterility testing suite received conditional approval.

The development represents the first major component to come online as part of the company's USD 85 million expansion at the Lexington site.

Piramal Pharma Solutions, part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is a global Contract Development and Manufacturing Organization. The new laboratory and sterility testing suite are designed for GMP drug product applications. Commercial-scale fill/finish capabilities, the remaining portion of the expansion, are expected to be online in late 2027.

Isolator and Grade C Suite Lift Sterility Testing Capacity

The dedicated sterility testing suite is a central feature of the new laboratory. It operates with a Grade C background environment, replacing the previously non-classified area used for this work. At its core is a fully integrated, Grade A sterility testing isolator that doubles the site's sterility testing capacity and permits multiple samples to be processed at the same time.

The isolator accommodates both open and closed filtration methods, giving the site flexibility to handle a broader range of product testing requirements. The suite also features built-in pass-throughs that transfer samples directly from the manufacturing floor into the laboratory, an arrangement that reduces contamination risk and protects product integrity.

Laboratory Footprint More Than Triples with Added Equipment

The new microbiology laboratory more than triples the microbiology testing space previously available at the Lexington site. The company says the larger footprint supports improved laboratory workflow and provides additional capacity to accommodate future growth.

Three new biosafety cabinets within the expanded space allow concurrent testing, which reduces sample queue times. All incubators have been consolidated within the new laboratory, streamlining workflow and improving monitoring and accessibility across testing activities.

Testing Time Reductions Expected to Speed Batch Releases

According to Piramal Pharma Solutions, the upgrades are expected to cut testing times by up to 50 percent. Faster testing is intended to accelerate batch releases, minimize bottlenecks, and ease transitions as client programs move from clinical to commercial stages.

The company adds that the new infrastructure strengthens the site's contamination control and sterility assurance capabilities, while the added testing capacity reduces supply risk and prepares the facility for commercial-scale demand.

Site Leadership on the Investment

"The new microbiology laboratory represents an important milestone in our Lexington expansion journey," said Nathan Richardson, VP and Site Head, Piramal Pharma Solutions Lexington.

"By enhancing sterility testing and microbiological quality capabilities, we are further strengthening our ability to support clients with high quality, reliable, and responsive services throughout the product life cycle. This investment reflects our continued commitment to operational excellence, patient safety, and the future growth of sterile injectable manufacturing in Lexington."

The company states that the new laboratory solidifies PPS' position in sterile injectables, enabling the Lexington site to serve small molecule, bioconjugate, and peptide modality clients worldwide.

Company Background

Piramal Pharma Solutions offers end-to-end development and manufacturing solutions across the drug life cycle as a Contract Development and Manufacturing Organization. The company serves customers through a globally integrated network of facilities in North America, Europe, and Asia.

Its services include drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, and commercial supply of APIs and finished dosage forms. PPS also provides specialized capabilities such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products.

Through Yapan Bio Private Limited, a subsidiary of Piramal Pharma Limited, the company offers development and manufacturing services for biologics including vaccines and gene therapies. Piramal Pharma Limited offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a distribution network in over 100 countries.

The company comprises Piramal Pharma Solutions; Piramal Critical Care, a complex hospital generics business; and the Piramal Consumer Healthcare business, which sells over-the-counter consumer and wellness products.

Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL and one of its associate companies, has emerged as one of the market leaders in its segment.